CB-020

N/A

Report date: 2024/07/19 17:54:33

Base Information

Drug NameCB-020

Drug Alias NameCB-020

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements

TargetsUpdating

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCaribou Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesCaribou Biosciences Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A